U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07329920) titled 'Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy' on Dec. 27, 2025.
Brief Summary: The aim of this study was to evaluate the clinical utility of mesenchymal CTC ratio dynamics as a real-time biomarker for PDAC patients with neoadjuvant therapy.
Study Start Date: July 10, 2018
Study Type: OBSERVATIONAL
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
Circulating Tumor Cells (CTCs)
Neoadjuvant Therapy
Intervention:
PROCEDURE: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance...